Results 171 to 180 of about 97,768,097 (202)

2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate

Cancer and Metastasis Reviews, 2000
2-Methoxyestradiol, once considered an inacitve end-metabolite of estradiol, has recently emerged as a very promising agent for cancer treatment. It is orally active in a wide range of tumor models, and inhibits tumor growth at doses showing no clinical signs of toxicity.
Victor S. Pribluda, Edward R. Gubish, Edward R. Gubish, Theresa M. LaVallee, Anthony Treston, Glenn M. Swartz, Shawn J. Green   +6 more
openaire   +2 more sources

Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension

Drug Development and Industrial Pharmacy, 2011
The aim of the present study was to evaluate the pharmacokinetic and antitumor activity of 2-methoxyestradiol (2-ME) nanosuspension relative to 2-ME solution both in vitro and in vivo. The pharmacokinetics of 2-ME administered either as a nanosuspension or as a solution were compared after I.V. administration to rats.
Shuzhang, Du, Ling, Zhu, Bin, Du, Xiufang, Shi, Zhenzhong, Zhang, Shuyu, Wang, Chaofeng, Zhang   +6 more
openaire   +2 more sources

Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships

Current Medicinal Chemistry, 2012
2-Methoxyestradiol (2ME2), a natural metabolite of estradiol which has no estrogenic activity, is a potent antitumor and anti-angiogenic compound, currently undergoing clinical trials for treatment of a variety of cancers. In the last two decades, an ever increasing number of synthetic 2-methoxyestradiol analogues have been reported. Structural changes
Jean-François, Peyrat, Jean-Daniel, Brion, Mouad, Alami   +2 more
openaire   +2 more sources

2-Methoxyestradiol as a Chemotherapeutic for Prostate Cancer

2004
Abstract : 2-Methoxyestradiol (2-ME) is an endogenous metabolite of estradiol with promise for cancer chemotherapy, including advanced prostate cancer. We have focused on events related to cell cycle arrest (G1 and G2/M) and induction of apoptosis in human prostate cancer cells.
openaire   +1 more source

2-Methoxyestradiol

Drugs of the Future, 2003
openaire   +1 more source

2-Methoxyestradiol

2002
Victor S. Pribluda, Theresa M. LaVallee, Shawn J. Green   +2 more
openaire   +1 more source

2-Methoxyestradiol

2008
openaire   +1 more source

2-Methoxyestradiol

2011
openaire   +1 more source

2-Methoxyestradiol

2016
openaire   +1 more source

Synthesis and Antitumor Activities of 3-Modified 2-Methoxyestradiol Analogs

Bioorganic and Medicinal Chemistry Letters, 2009
Theresa M Lavallée, Gregory E Agoston, Anthony M Treston   +2 more
exaly